Loading people...
Daanish Jamal is an Associate at SR One, a transatlantic life sciences venture capital firm, based in the San Francisco Bay Area. Over the past four years at the firm, he has focused on biotechnology investments and previously served as an Entrepreneur in Residence. Prior to joining SR One, Jamal worked as an Associate Partner at GreatPoint Ventures and held business development and operations roles at Skyhawk Therapeutics and Dragonfly Therapeutics. His investment experience includes serving as a Board Observer for several healthcare and biotech startups, including Odyssey Therapeutics, Guide Therapeutics, and Truvian. He began his career as a Research Analyst at One Market Capital after earning a Bachelor of Science in Business Administration in Finance from Georgetown University. Jamal maintains a primary professional focus on executing venture capital investments across the biotechnology and healthcare sectors.
Daanish Jamal is a key member of the investment team at SR One, a distinguished venture capital firm with a rich history of fostering innovation in the life sciences sector. As an Associate, Daanish is deeply involved in the firm's core activities, which include sourcing new investment opportunities, conducting thorough due diligence, and providing strategic support to SR One's diverse portfolio companies.
SR One is renowned for its commitment to early-stage investments in biotechnology, pharmaceuticals, and healthcare technology. The firm seeks out companies that are developing novel therapeutics, diagnostics, and platforms with the potential to significantly impact patient care and advance medical science. Daanish Jamal's role is integral to this process, as he leverages his analytical skills and industry insights to identify promising ventures that align with SR One's investment thesis.
While specific details of Daanish Jamal's career background are not publicly detailed, individuals in his position at leading life sciences VC firms typically possess a strong foundation in science, often holding advanced degrees in relevant fields such as biology, biochemistry, or pharmacology. This academic rigor is frequently complemented by experience in research, consulting, or prior roles within the biotech or pharmaceutical industry. Such a background equips Associates like Daanish with the critical understanding needed to assess complex scientific data, evaluate market potential, and identify the key drivers of success for early-stage life sciences companies.
At SR One, Daanish contributes to the firm's robust investment strategy, which emphasizes long-term partnerships with visionary entrepreneurs. He works closely with senior partners to analyze market trends, evaluate competitive landscapes, and build financial models that inform investment decisions. His contributions help SR One continue its legacy of backing companies that bring revolutionary treatments and technologies to market. Though specific notable investments led by Daanish Jamal are not publicly disclosed, his work is vital in supporting the firm's overall portfolio, which includes numerous successful and impactful companies across the life sciences spectrum.
Through his dedication and expertise, Daanish Jamal helps SR One maintain its position at the forefront of life sciences venture capital, driving innovation and supporting the next generation of healthcare breakthroughs.
Daanish Jamal is an Associate at SR One, a leading venture capital firm focused on investing in early-stage life sciences companies. He plays a key role in identifying and evaluating new investment opportunities.
As an Associate at SR One, Daanish Jamal contributes to investments in early-stage biotechnology, pharmaceuticals, and healthcare technology companies. SR One focuses on novel therapeutics, diagnostics, and platforms with significant potential for medical advancement.
Daanish Jamal works at SR One, a prominent venture capital firm dedicated to investing in the life sciences sector. SR One backs innovative companies across biotechnology and healthcare technology.
